EZH2 and cancer: An emerging target therapy for cancer treatment in preclinical studies is the EZH2 lysine methyltransferase inhibitors, with great results especially in combination with radiotherapy or chemotherapy, such as cisplatin, gefitinib and tamoxifen (Duan et al., 2020; Morel et al., 2020).